Under the terms of the definitive agreement, Calytrix Bio shareholders could receive the total cash, including an initial upfront payment followed by subsequent payouts contingent on reaching specified clinical and regulatory milestones.
Engineered to provide pan-mutant activity, the antibody binds both Type 1 and Type 2 (mCALR) expressed on tumour-specific cell surfaces.
This targeted mechanism is intended to eradicate disease-driving mutant clones while avoiding damage to healthy tissues and preserving normal haematopoiesis.
The antibody also features a convenience and safety profile aimed at supporting initial therapeutic intervention alongside extended, long-term administration.
The biological profile addresses an unmet therapeutic need in the management of myeloproliferative neoplasms (MPNs).
By focusing directly on the genetic alterations driving disease progression, the Calytrix Bio candidate is intended to provide a targeted, disease-modifying alternative.
Calytrix Bio president and CEO Brad Prosek said: “Calytrix was founded on the belief that patients with MPNs deserve therapies that do more than manage symptoms. From the beginning, our goal has been to alter the disease course in mCALR-driven ET and MF.
“This transaction represents an important step toward accelerating that vision. We look forward to Lilly advancing the programme through the clinic and exploring its potential to benefit patients across the disease spectrum.
“I am deeply grateful to our team, scientific advisors, and committed investors, each of whom has supported delivery of Calytrix’s programme to the starting line for clinical development.”
Based in Wellesley Hills, Massachusetts, Calytrix Bio was established in 2025 by J.P. Morgan Life Sciences Private Capital, the life sciences venture capital division of J.P. Morgan Asset Management.
Last month, Lilly expanded its partnership and licensing agreement with California-based biotech, Gate Bioscience, to develop molecular gate therapies targeting difficult-to-drug proteins. Lilly has been the most prolific dealmaking company in big pharma so far this year.